WDR12 Antibody

What is WDR12 and why is it significant for research?

WDR12 is a WD40 repeat protein that functions as a component of the PeBoW complex, which is required for maturation of 28S and 5.8S ribosomal RNAs and formation of the 60S ribosome . It plays a crucial role in processing the 32S precursor ribosomal RNA and cell proliferation . Research significance stems from:

• Essential role in fundamental cellular processes like ribosome biogenesis

• Regulation by c-Myc, suggesting involvement in cell growth control mechanisms

• Potential oncogenic effects across various human malignancies

• Correlation with immune infiltration in tumor microenvironments

WDR12 localizes predominantly to the nucleolus with diffuse nucleoplasmic distribution, similar to its yeast homologue Ytm1p . Expression studies show it accumulates in proliferating cells compared to arrested cells, indicating its importance in cell proliferation pathways .

What experimental methods can validate WDR12 antibody specificity?

Validating antibody specificity is critical for reliable WDR12 research. Recommended validation protocols include:

• Western blot analysis with positive controls (e.g., HeLa cells) to confirm detection of the expected molecular weight band

• Gradient protein loading (5-50 μg) to assess sensitivity and signal linearity, as demonstrated in validation studies

• Knockdown/knockout experiments to verify signal reduction/elimination

• Cross-reactivity testing with the target protein from different species (current commercial antibodies have demonstrated reactivity with both human and mouse WDR12)

• Comparison between different antibody clones or types (polyclonal vs. monoclonal)

Validation data should show consistent detection across multiple experimental repeats and correlation with other detection methods like mass spectrometry or RNA expression.

How should WDR12 antibodies be applied in immunofluorescence studies?

For optimal immunofluorescence analysis of WDR12:

• Fixation method: Select protocols that preserve nuclear and nucleolar structures

• Co-staining: Include nucleolar markers like nucleophosmin to confirm the predominant nucleolar localization of WDR12

• Controls: Include WDR12-eYFP fusion proteins as positive controls, which exhibit diffuse nucleoplasmic distribution with strong nucleolar accumulation

• Imaging parameters: Adjust microscope settings to capture both intensive nucleolar signal and more diffuse nucleoplasmic distribution

• Quantification: Compare the relative distribution between nucleolar and nucleoplasmic compartments

Research has confirmed that endogenous WDR12 localizes to both nucleolus and nucleoplasm in various cell lines including U2OS, HeLa, and WI-38 . Fluorescent protein tagging studies show strong co-localization with nucleophosmin, reinforcing its nucleolar function .

What are the optimal conditions for using WDR12 antibodies in Western blot analysis?

Based on published methodologies, optimal Western blot conditions include:

When analyzing WDR12 expression changes, consider that proliferation status significantly impacts expression levels, with higher expression in proliferating cells versus arrested cells .

How can WDR12 antibodies be used to study the PeBoW complex?

For investigating WDR12's role in the PeBoW complex:

• Co-immunoprecipitation: Use WDR12 antibodies to pull down the complex and confirm interactions with Pes1 and Bop1 under various cellular conditions

• Comparative expression analysis: Monitor expression of all three components (WDR12, Bop1, and Pes1) using specific antibodies to analyze coordinated regulation

• Deletion mutants: Generate and express deletion mutants (such as WDR12ΔNle) and use antibodies to confirm expression and study effects on PeBoW complex assembly

• Cell cycle analysis: Correlate WDR12 expression with cell cycle phases, as WDR12ΔNle expression leads to cell cycle arrest

• Functional studies: Use BrdU light assays in combination with WDR12 antibody detection to investigate how manipulating WDR12 affects cell proliferation

Studies have shown that WDR12, Bop1, and Pes1 are coordinately regulated in response to c-Myc expression, with all three proteins accumulating following conditional c-Myc activation .

How does WDR12 expression correlate with cell proliferation, and how can this be measured?

WDR12 expression strongly correlates with cell proliferation status:

• Proliferating P493-6 cells express high levels of WDR12, Bop1, and Pes1 compared to arrested cells

• WDR12 accumulates following conditional c-Myc expression, linking it to growth-promoting pathways

• WDR12ΔNle (N-terminal Notchless-like domain deletion mutant) expression induces cell cycle arrest without increasing apoptosis

Methodologies to assess this correlation include:

• Comparative Western blot analysis between proliferating and growth-arrested cell populations

• BrdU light assays to determine whether manipulating WDR12 (e.g., expressing WDR12ΔNle) affects cell cycle progression

• Flow cytometry to analyze cell cycle distribution following WDR12 manipulation, which has shown that WDR12ΔNle expression leads to G1 accumulation and reduced S phase

• Correlation with proliferation markers like Ki-67 in tissue samples

How can WDR12 antibodies be utilized in cancer research?

WDR12 antibodies offer multiple applications in cancer research:

• Expression profiling: Quantify WDR12 protein levels across diverse tumor types to correlate with clinical outcomes

• Comparative analysis: WDR12 is significantly upregulated in multiple cancers including BLCA, BRCA, CESC, GBM, CHOL, COAD, ESCA, HNSC, LIHC, LUAD, LUSC, PRAD, READ, STAD, and UCEC compared to normal tissues

• Prognostic indicator assessment: Evaluate WDR12 as a potential biomarker by correlating expression with patient survival data

• Tumor microenvironment analysis: Investigate relationships between WDR12 expression and immune cell infiltration, particularly myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs)

• Correlation studies: Analyze associations between WDR12 expression and important clinical parameters like tumor mutation burden (TMB) and microsatellite instability (MSI)

Pan-cancer analyses have revealed significant positive correlations between WDR12 expression and MSI in multiple cancers including PRAD, LIHC, PAAD, CESC, BRCA, STAD, KIRC, KICH, and HNSC .

What is the relationship between WDR12 expression and immune cell infiltration in tumors?

Research has revealed significant correlations between WDR12 expression and immune cell infiltration:

• Positive correlation with myeloid-derived suppressor cells (MDSCs) in ACC, LIHC, LUAD, PRAD, READ, and SKCM

• Negative correlation with cancer-associated fibroblasts (CAFs) in the same tumors

• Negative correlation with NK T cells across all tumors with significant results, suggesting an immunosuppressive role of WDR12

• Negative correlation with CD8+ T cells in HNSC, KIRC, KIRP, STAD, THCA, and UCS, but positive correlation in BRCA and UVM

These findings suggest WDR12 may modulate the tumor immune microenvironment through:

• Promoting immunosuppressive cell infiltration (MDSCs)

• Inhibiting anti-tumor immune cells (NK T cells and CD8+ T cells in most tumors)

• Interfering with stromal components (CAFs)

Methodologically, researchers can investigate these relationships using:

• Multiplex immunohistochemistry with WDR12 antibodies and immune cell markers

• Correlation analysis between WDR12 expression and immune cell infiltration scores from algorithms like TIMER, CIBERSORT, and QUANTISEQ

How does WDR12 expression relate to tumor mutation burden and microsatellite instability?

WDR12 expression shows significant correlations with cancer genomic features:

These correlations suggest WDR12 might influence genomic stability or reflect underlying mutational processes . This relationship is particularly relevant since:

• TMB is a promising therapeutic marker for immunotherapy response

• MSI serves as a biomarker for immune-checkpoint inhibitors

• Both features are linked to cancer progression and treatment response

Researchers can investigate these relationships by correlating WDR12 protein expression with TMB and MSI scores derived from genomic analyses .

What techniques can identify and characterize WDR12 binding partners?

To identify WDR12 interacting proteins:

• Experimental validation using the STRING database with parameters set to "Low confidence" interaction scoring and "experiments" as active interaction sources

• GEPIA2's 'Similar Gene' module to identify the top 100 WDR12-correlated genes

• Co-expression analysis using TIMER2's 'Gene_Corr' module to generate heatmap data for genes of interest

• GO and KEGG pathway enrichment analysis using the DAVID database to identify biological processes and pathways associated with WDR12 and its interacting partners

For physical interaction studies:

• Co-immunoprecipitation with WDR12 antibodies followed by mass spectrometry

• Yeast two-hybrid screening to identify direct protein-protein interactions

• Proximity labeling techniques like BioID to identify proteins in close proximity to WDR12

What are common challenges when working with WDR12 antibodies and how can they be addressed?

When troubleshooting, remember that WDR12 expression is significantly higher in proliferating cells compared to arrested cells, which may explain apparent inconsistencies between samples with different proliferation states .

How should researchers interpret WDR12 expression differences across cancer types?

When analyzing WDR12 expression across cancer types:

• Consider tissue-specific contexts: WDR12 shows significant upregulation in multiple cancers including BLCA, BRCA, CESC, GBM, CHOL, COAD, ESCA, HNSC, LIHC, LUAD, LUSC, PRAD, READ, STAD, and UCEC compared to normal tissues

• Examine expression by cancer stage: Analyze whether WDR12 expression correlates with pathological stages using GEPIA2's 'Pathological Stage Plot' module

• Compare protein vs. mRNA levels: Check consistency between transcriptomic and proteomic data using databases like CPTAC

• Evaluate methylation status: WDR12 methylation patterns may explain expression differences and can be analyzed using databases like UALCAN, SMART, and MEXPRESS

• Consider molecular subtypes: Expression patterns may differ between molecular subtypes of the same cancer

• Correlate with immune profiles: Different cancers show varying relationships between WDR12 and immune cell infiltration

Comprehensive pan-cancer analysis has revealed that WDR12 is significantly upregulated in multiple cancers, suggesting a potential common oncogenic role across different tumor types .

How does WDR12 expression correlate with immune-related molecules?

Analysis of WDR12's relationship with immune-related molecules reveals:

• Most immune-related genes show significant correlations with WDR12 expression

• The majority of these correlations are negative across most malignancies

• Specific correlations exist with:

  • Immunostimulators (e.g., CD276)

  • Immunoinhibitors (e.g., IL10RB)

  • MHC-related molecules (e.g., TAP2)

  • Tumor-infiltrating lymphocytes (TILs)

  • Chemokines and their receptors

This data suggests WDR12 may influence tumor progression by modulating immune-related molecules and consequently affecting anti-tumor immune responses . These findings have potential implications for cancer immunotherapy development, as they identify WDR12 as a possible regulator of the tumor immune microenvironment .

Methodologically, researchers can further investigate these relationships using correlation analysis and functional studies to determine whether WDR12 directly regulates these immune-related molecules or if these correlations reflect broader gene expression programs.

What emerging techniques could enhance WDR12 antibody-based research?

Emerging methodologies that could advance WDR12 research include:

• Single-cell proteomics to analyze WDR12 expression heterogeneity within tumors

• Spatial proteomics to map WDR12 distribution relative to tumor microenvironment components

• Proximity labeling techniques (BioID/TurboID) to identify local interactomes of WDR12 in different cellular compartments

• CRISPR screens to identify synthetic lethal interactions with WDR12 in cancer cells

• Targeted protein degradation approaches to study acute WDR12 depletion effects

• Mass cytometry (CyTOF) to simultaneously analyze WDR12 expression and immune marker profiles at single-cell resolution